- Home
- SBS vs INCY Comparison
SBS vs INCY Comparison
Compare SBS & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBS
- INCY
- Stock Information
- Founded
- SBS 1954
- INCY 1991
- Country
- SBS Brazil
- INCY United States
- Employees
- SBS N/A
- INCY N/A
- Industry
- SBS Water Supply
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- SBS Utilities
- INCY Health Care
- Exchange
- SBS Nasdaq
- INCY Nasdaq
- Market Cap
- SBS 14.4B
- INCY 17.0B
- IPO Year
- SBS 2002
- INCY 1993
- Fundamental
- Price
- SBS $25.66
- INCY $105.22
- Analyst Decision
- SBS
- INCY Buy
- Analyst Count
- SBS 0
- INCY 19
- Target Price
- SBS N/A
- INCY $89.19
- AVG Volume (30 Days)
- SBS 834.8K
- INCY 2.8M
- Earning Date
- SBS 11-10-2025
- INCY 10-28-2025
- Dividend Yield
- SBS 2.13%
- INCY N/A
- EPS Growth
- SBS 174.82
- INCY 3878.02
- EPS
- SBS 3.00
- INCY 5.90
- Revenue
- SBS $7,382,628,649.00
- INCY $4,813,105,000.00
- Revenue This Year
- SBS N/A
- INCY $19.33
- Revenue Next Year
- SBS $11.93
- INCY $10.47
- P/E Ratio
- SBS $8.53
- INCY $17.95
- Revenue Growth
- SBS 48.83
- INCY 18.09
- 52 Week Low
- SBS $13.87
- INCY $53.56
- 52 Week High
- SBS $25.88
- INCY $106.47
- Technical
- Relative Strength Index (RSI)
- SBS 70.38
- INCY 79.03
- Support Level
- SBS $24.28
- INCY $91.16
- Resistance Level
- SBS $25.88
- INCY $106.47
- Average True Range (ATR)
- SBS 0.38
- INCY 4.10
- MACD
- SBS 0.12
- INCY 1.59
- Stochastic Oscillator
- SBS 88.15
- INCY 94.41
About SBS Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp (Each repstg 250)
Companhia De Saneamento Basico Do Estado De Sao Paulo is engaged in the provision of basic and environmental sanitation services in the Sao Paulo State and supplies treated water and sewage services on a wholesale basis. The company operates in a single segment, which is Sanitation services.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.